{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Leiomyosarcoma&page=2", "query": { "condition": "Advanced Leiomyosarcoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Leiomyosarcoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T09:45:27.665Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07125183", "title": "Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "65 Years to 100 Years" }, "enrollment_count": 20, "start_date": "2026-12", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-05-22T09:45:27.665Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07125183" }, { "nct_id": "NCT01343277", "title": "A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Liposarcoma or Leiomyosarcoma" ], "interventions": [ { "name": "Trabectedin", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 579, "start_date": "2011-06", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2016-08-26", "last_synced_at": "2026-05-22T09:45:27.665Z", "location_count": 77, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 74 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01343277" }, { "nct_id": "NCT00856050", "title": "Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leiomyosarcoma" ], "interventions": [ { "name": "letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 27, "start_date": "2009-02", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-05-22T09:45:27.665Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00856050" }, { "nct_id": "NCT05432791", "title": "Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Locally Advanced Uterine Corpus Leiomyosarcoma", "Metastatic Uterine Corpus Leiomyosarcoma", "Stage III Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8", "Unresectable Uterine Corpus Leiomyosarcoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Trabectedin", "type": "DRUG" }, { "name": "Transthoracic Echocardiography Test", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2023-03-30", "completion_date": "2027-01-30", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-05-22T09:45:27.665Z", "location_count": 144, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 120 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Dublin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05432791" }, { "nct_id": "NCT00654160", "title": "Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anal Cancer", "Carcinoma of the Appendix", "Colorectal Cancer", "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Gastric Cancer", "Gastrointestinal Carcinoid Tumor", "Gastrointestinal Stromal Tumor", "Liver Cancer", "Pancreatic Cancer", "Small Intestine Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 7, "start_date": "2008-06", "completion_date": "2012-12-03", "has_results": false, "last_update_posted_date": "2017-05-25", "last_synced_at": "2026-05-22T09:45:27.665Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00654160" }, { "nct_id": "NCT05116800", "title": "Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Soft Tissue Sarcoma", "Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma", "Leiomyosarcoma", "Liposarcoma", "Angiosarcoma", "Synovial Sarcoma", "Rhabdomyosarcoma", "Spindle Cell Sarcoma", "High Grade Sarcoma", "Bone Sarcoma", "Osteosarcoma", "Ewing Sarcoma of Bone" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "9-ING-41", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 0, "start_date": "2022-03-01", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2021-12-07", "last_synced_at": "2026-05-22T09:45:27.665Z", "location_count": 2, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05116800" }, { "nct_id": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Carcinoma of the Appendix", "Estrogen Receptor-negative Breast Cancer", "Extensive Stage Small Cell Lung Cancer", "Gastrointestinal Stromal Tumor", "HER2-negative Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Progesterone Receptor-negative Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Cell Lung Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Small Intestine Adenocarcinoma", "Small Intestine Leiomyosarcoma", "Small Intestine Lymphoma", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Triple-negative Breast Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "7-hydroxystaurosporine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-05-22T09:45:27.665Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031681" }, { "nct_id": "NCT06308419", "title": "A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leiomyosarcoma", "Soft-tissue Sarcomas" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2024-08-14", "completion_date": "2031-02-01", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-05-22T09:45:27.665Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06308419" }, { "nct_id": "NCT01189253", "title": "Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "trabectedin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2011-05", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2014-08-08", "last_synced_at": "2026-05-22T09:45:27.665Z", "location_count": 8, "location_summary": "Santa Monica, California • Stanford, California • Iowa City, Iowa + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01189253" }, { "nct_id": "NCT04906876", "title": "A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma", "Soft Tissue Sarcoma", "Metastatic Sarcoma", "Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma", "Leiomyosarcoma", "Liposarcoma", "Angiosarcoma", "Synovial Sarcoma", "Rhabdomyosarcoma", "Spindle Cell Sarcoma", "High Grade Sarcoma", "Bone Sarcoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "9-ING-41", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 0, "start_date": "2021-09", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2021-07-28", "last_synced_at": "2026-05-22T09:45:27.665Z", "location_count": 2, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906876" } ] }